Optimizing anti-PI3Kδ and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events
Our data demonstrated that refining immunotherapy delivery approaches can improve tolerability that ultimately transforms treatment success.
Authors
- Emily M. Mills
- Andrew Godkin
- Kathryn Smart
- Awen Gallimore
- Sarah N. Lauder (ORCID: https://orcid.org/0000-0003-2561-6277)
- Ana Pires (ORCID: https://orcid.org/0000-0001-7316-344X)
- Michelle Somerville
- Lorenzo Capitani (ORCID: https://orcid.org/0000-0003-1232-569X)
- James K. Geary
- Bart Vanhaesebroeck
Institutions
- CRUK Lung Cancer Centre of Excellence (GB)
- University College London (GB)
- Cardiff University (GB)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-012157
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00